5450 Chemin de la Côte-des-Neiges

Suite 522

Montréal, Qc

H3T 1Y6

514-282-4523

info@exactis.ca

  • White LinkedIn Icon
Send Us a Message

© 2018 by Exactis Innovation

Molecular Pathology Services

High-quality clinical biospecimens are critical to decipher the molecular basis of cancer and are a requirement for translational research. Our laboratory team applies rigorous standard operating procedures for collection, processing and storage of next-generation biospecimen (ref: Basik et al, 2013) with quality control of all samples, allowing subsequent multi-dimensional high-throughput profiling.

Through our network, we offer: 

  • Sample management:

  • Sample procurement, embedding (OCT and paraffin blocks), sectioning and macro-dissection of tissue blocks

  • Histological evaluation by board-certified pathologists

  • DNA isolation: microgram quantities of high molecular weight DNA isolated from blood and tissues specimen (snap frozen, FFPE and RNAlater-treated samples)

  • RNA isolation: microgram quantities of total RNA with high integrity number

  • Sample quality assessment by electrophoresis gels, picogreen and Agilent 2100 Bioanalyzer measurements

  • Plasma isolation

  • Storage of samples at optimal temperature including paraffin and OCT blocks, slides, plasma, whole blood, buffy coats, DNA and RNA

  • Document and data archiving: requisition forms, histopathology reports, sample histopathology and quality control information

High-Throughput Profiling Data Analysis

Primary and metastasis lesions, as well as liquid biopsies, are collected from patients at distinct time points during their treatment in a pre-specified clinical context.

 

Sample profiling is carried out across multiple independent omic platforms to identify therapy resistant signatures and characterize molecular changes during treatment. Biopsies are profiled using exome and transcriptome (mRNA and miRNA) sequencing as well as high density SNP array. Additionally, serial blood samples are collected for proteomic, ctDNA and cytokine analysis. ​

  • Genome and exome-sequencing

  • RNA-sequencing

  • ctDNA targeted sequencing

  • Cytogenetics

  • Proteomics

 

Our multi-omic approach and integration of independent molecular platforms to profile sequential lesions and blood samples offers new opportunities to investigate mechanisms of drug resistance, develop and validate biomarkers, identify discordance between primary tumours and metastases and clonal evolution features that can be targeted for drug development and guide therapy.